Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02523924 · ClinicalTrials.gov registry record · NA
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
A NA study of Adenocarcinoma of the Prostate, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02523924: Completed NA study of Adenocarcinoma of the Prostate, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT02523924 is a NA study of Adenocarcinoma of the Prostate that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 50 participants, below the 107-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02523924, a NA study of Adenocarcinoma of the Prostate, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.
Primary Outcome
Number of sites with 18F-DCFPyL uptake consistent with prostate cancer.
Conditions Studied
Interventions
- DRUG 18F-DCFPyL
Study Locations (1)
Maryland
- SKCCC - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-06-02 |
| Est. Completion | 2019-03-04 |
| Phase | NA |
What the finished NCT02523924 record still lists
NCT02523924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 107-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 1 intervention - of which 18F-DCFPyL is the first listed.
NCT02523924 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02523924 about?
NCT02523924 is a clinical study titled "Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy". This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.
What is the current status of trial NCT02523924?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2015-06-02. Estimated completion is 2019-03-04.
What conditions does trial NCT02523924 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Prostate.
What interventions are being tested in trial NCT02523924?
The interventions under investigation include: 18F-DCFPyL (DRUG).
Who is sponsoring clinical trial NCT02523924?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02523924 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02523924's enrollment target sits among peer trials
50 9th of 21 higher than 13 of 21 other Adenocarcinoma of the Prostate trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma of the Prostate trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · NA
-
Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
ACTIVE NOT RECRUITING · NA
-
Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer
COMPLETED · NA
-
Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping
COMPLETED · NA
-
Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound
COMPLETED · NA
-
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI